89BIO (ETNB)
(Delayed Data from NSDQ)
$8.86 USD
+0.39 (4.55%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $8.85 -0.01 (-0.06%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Income Statements
Fiscal Year end for 89BIO falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 151 | 102 | 90 | 49 | 27 |
Income After Depreciation & Amortization | -151 | -102 | -90 | -49 | -27 |
Non-Operating Income | 18 | 2 | -1 | 0 | -31 |
Interest Expense | 5 | 2 | 0 | 0 | 0 |
Pretax Income | -138 | -102 | -90 | -50 | -57 |
Income Taxes | 4 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -142 | -102 | -90 | -50 | -57 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -142 | -102 | -90 | -50 | -57 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -157 | -102 | -88 | -49 | -27 |
Depreciation & Amortization (Cash Flow) | -5 | 0 | 2 | 1 | 0 |
Income After Depreciation & Amortization | -151 | -102 | -90 | -49 | -27 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 71.17 | 34.81 | 20.10 | 16.09 | 2.34 |
Diluted EPS Before Non-Recurring Items | -2.00 | -2.93 | -4.48 | -3.08 | -24.49 |
Diluted Net EPS (GAAP) | -2.00 | -2.93 | -4.48 | -3.08 | -24.49 |
Fiscal Year end for 89BIO falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 53.44 | 57.28 | 41.20 | 39.35 | 42.13 |
Income After SG&A, R&D, and Dept/Amort Expenses | -53.44 | -57.28 | -41.20 | -39.35 | -42.13 |
Non-Operating Income | 6.47 | 6.56 | 5.70 | 5.58 | 4.63 |
Interest Expense | 0.87 | 0.86 | 0.87 | 0.96 | 0.89 |
Pretax Income | -47.84 | -51.58 | -36.37 | -34.73 | -38.39 |
Income Taxes | 0.13 | 0.10 | 3.87 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -47.97 | -51.68 | -40.24 | -34.73 | -38.39 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -47.97 | -51.68 | -40.24 | -34.73 | -38.39 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 99.83 | 95.85 | 80.70 | 76.34 | 74.13 |
Diluted EPS Before Non-Recurring Items | -0.48 | -0.54 | -0.50 | -0.45 | -0.52 |
Diluted Net EPS (GAAP) | -0.48 | -0.54 | -0.49 | -0.45 | -0.52 |